E-CLAD UK Long-term
Research type
Research Study
Full title
Extracorporeal Photopheresis in the treatment of Chronic Lung Allograft Dysfunction: Long-Term Follow-Up Study
IRAS ID
338850
Contact name
Andrew Fisher
Contact email
Sponsor organisation
The Newcastle upon Tyne Hospitals NHS Foundation Trust
Duration of Study in the UK
3 years, 2 months, 0 days
Research summary
The E-CLAD UK trial explores the impact of Extracorporeal Photopheresis, known as ECP, in lung transplant patients experiencing chronic rejection, a condition where the body starts to reject the transplanted lungs. Chronic rejection is also known as Chronic Lung Allograft Dysfunction (CLAD). That trial followed participants for a period of 24 weeks from the start of treatment. While E-CLAD UK provides information on the short-term impact of treatment on health it is unable to tell us of the long-term impact the treatment has on health. This long-term follow-up study will follow participants up until two years after they joined the original trial, providing important information on the wider impact the treatment has on health and health care utilisation.
REC name
West Midlands - South Birmingham Research Ethics Committee
REC reference
24/WM/0075
Date of REC Opinion
22 Apr 2024
REC opinion
Favourable Opinion